Report

Blood Preparation Market Analysis

The blood preparation market size was valued at USD 56.55 billion in 2025 and is forecast to reach USD 76.50 billion by 2030, registering a 6.23% CAGR during the period. This trajectory is supported by the growing adoption of automated component separation, the spread of pathogen-reduction platforms, and steady growth in surgical volumes that elevate transfusion demand. Parallel expansion in plasma-derived therapeutics, especially immunoglobulins, underscores a move toward precision medicine and chronic-disease management. Consolidation among plasma fractionators is lowering cost per liter and improving supply resilience, while new anticoagulant classes such as factor XI inhibitors are widening clinical use cases. Across regions, robust regulatory frameworks in North America and capacity build-outs in Asia-Pacific create a balanced demand-supply dynamic that sustains long-term growth for the blood preparation market.

Global Blood Preparation Market Trends and Insights



Increasing Global Surgical Procedures Volume

Elective and trauma-related surgeries are rebounding in 2025, boosting demand for red-cell concentrates and plasma components. Hospitals in the United States increased orthopedic procedure counts by 8% year-on-year, prompting upgrades in component storage and rapid-type testing. Similar momentum is visible in Western Europe, where minimally invasive techniques encourage outpatient surgeries that still require pre-operative blood matching. Automated cross-matching analyzers and digital blood-bank software shorten turnaround times, improving utilization rates for every donated unit. These developments strengthen revenue visibility for the blood preparation market.

Growing Prevalence of Chronic and Hematologic Disorders

Chronic kidney disease, hematologic cancers, and hemophilia continue to rise across Asia-Pacific, expanding recurring demand for plasma-derived immunoglobulins and coagulation factors. Government reimbursement lists in China and India now include subcutaneous immunoglobulin therapy, accelerating patient access. Multinationals respond by adding fractionation lines and donor centers, while domestic firms partner for technology transfer. The broad disease burden ensures long-term pull for blood derivatives, reinforcing sustainable growth for the blood preparation market.

Risk of Transfusion-Transmitted Infections

Studies in Uganda reported 13.8% prevalence of transfusion-transmitted infections among donors, with HBV and HCV notably high. While pathogen-reduction systems cut malaria transmission risk by 87%, budget limitations hinder adoption where the threat is greatest. International-donor agencies fund pilot programs, yet scalability lags behind infection growth. The persistent gap emphasizes the need for affordable sterilization, tempering absolute growth of the blood preparation market.

Other drivers and restraints analyzed in the detailed report include:

Rising Government Support for Blood Collection Infrastructure / Advancements in Blood Screening and Processing Technologies / High Cost of Advanced Blood Preparation Technologies /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Blood derivatives held 48.45% of 2024 revenue, anchored by strong immunoglobulin and coagulation factor demand. The pulmonary embolism segment accounted for 27.56% share of the blood preparation market size in 2024, supporting derivative consumption in acute settings. CSL Behring logged 20% sales growth for immunoglobulins, aided by a 22% drop in plasma collection cost per liter, illustrating scale economics that favor large fractionators. Automated systems such as Reveos drive 8.56% CAGR for blood components, delivering higher platelet and red-cell yields per unit, lowering wastage, and extending storage times from 42 to 63 days through super-cooling preservation. Increasing hospital adoption of component-specific transfusion protocols sustains this expansion for the blood preparation market.

The derivatives pipeline remains buoyant. Grifols projects USD 1 billion cumulative sales for Yimmugo over seven years post-FDA approval. European governments aim to reach 80% self-sufficiency in albumin by 2030, stimulating domestic contract fractionation programs. Parallel advances in whole-blood robotics and artificial substitutes offer long-range alternatives but will take time to displace established derivatives. Consequently, derivatives retain leadership even as component innovation elevates the efficiency and profitability of the blood preparation market.

Anticoagulants represented 61.45% of 2024 revenue, reflecting entrenched clinical guidelines and physician familiarity. Abelacimab, a factor XI inhibitor, reduced bleeding by 67% versus rivaroxaban in atrial-fibrillation trials, propelling platelet-aggregation inhibitor growth at an 8.73% CAGR. Apixaban remained Australia's most prescribed oral anticoagulant, costing the health system USD 500 million in 2024. The pulmonary embolism segment captured 27.56% share of the blood preparation market, reinforcing anticoagulant volumes across emergency and chronic settings.

Four-factor prothrombin complex concentrate is displacing frozen plasma during cardiac surgery, lowering major bleeding by nearly 50%. Fibrinolytics hold steady demand but face increasing competition from recombinant hemostatic drugs that shorten infusion times. As factor XI agents enter late-stage development, prescribing patterns may pivot, but established anticoagulants will continue to anchor revenue for the blood preparation market during the forecast horizon.

The Blood Preparation Market Report is Segmented by Product Type (Whole Blood, Blood Components, and Blood Derivatives), Blood Thinning Agents (Anticoagulants, and More), Application (Thrombocytosis, and More), End User (Hospitals & Surgical Centers, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America retained 38.54% of 2024 revenue, underpinned by 350 CSL Plasma donor centers and rapid uptake of the Rika collection system, which cuts donation time by 15 minutes. The region's elaborate regulatory agenda, with five blood-focused guidance documents slated for 2025, accelerates technology approval and adoption. Yet climate disruptions dent supply: the American Red Cross saw a 25% inventory drop in July 2024 during extreme heat and storms.

Asia-Pacific registers the highest 7.56% CAGR. Terumo's USD 15 million Hangzhou plant enhances local production, while Indonesia's plasma-fractionation project fast-tracks regional self-sufficiency. Japan's artificial-blood program at Nara Medical University could revolutionize emergency transfusion with two-year shelf life and universal compatibility.

Europe focuses on autonomy under the new SoHO regulation, requiring 2 million extra donors and common quality standards across member states. The United Kingdom is on track for 25% immunoglobulin self-sufficiency by 2025, aided by domestic fractionation contracts gov.uk. Sanquin's adoption of automated processing in the Netherlands demonstrates how technology reduces dependence on incremental donations. These geographic dynamics collectively reinforce a balanced global outlook for the blood preparation market.

List of Companies Covered in this Report:

CSL Behring / Takeda Pharmaceutical Co. / Baxter / Grifols / Octapharma / Pfizer / Bayer / Sanofi / Bristol-Myers Squibb / Boehringer Ingelheim / Daiichi Sankyo / GlaxoSmithKline / Leo Pharma / Abbott Laboratories / Haemonetics / Terumo / Fresenius / Medtronic PLC (Blood Management) / American Red Cross / Kedrion Biopharma /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /